Clinical TrialJun 1, 2026, 04:51 PM
Immuneering's atebimetinib shows 17.3-month mOS in pancreatic cancer
AI Summary
Immuneering Corporation announced updated positive data from its Phase 2a clinical trial of atebimetinib in combination with mGnP for first-line pancreatic cancer. The trial showed a median overall survival of 17.3 months, significantly exceeding the 8.5 months reported for standard of care. The drug was generally well-tolerated, with no new safety signals. The company also outlined key upcoming milestones, including the initiation of a pivotal Phase 3 trial for atebimetinib in pancreatic cancer in mid-2026 and a new clinical trial in non-small cell lung cancer in H2 2026.
Key Highlights
- Atebimetinib showed 17.3-month median overall survival (mOS) in 55 pancreatic cancer patients.
- This compares favorably to the 8.5-month mOS reported for the standard of care.
- Median progression-free survival (mPFS) was 8.3 months in the 320 mg ITT Population.
- Overall response rate (ORR) was 36% (18/50 patients) and disease control rate (DCR) was 82% (41/50 patients).
- 84% of patients maintained weight stability; no Grade 5 adverse events observed.
- Pivotal Phase 3 trial (MAPKeeper 301) for pancreatic cancer to begin dosing mid-2026.
- New clinical trial in non-small cell lung cancer to begin dosing in H2 2026.
- IND-enabling studies for next Deep Cyclic Inhibition® product candidate to begin mid-2027.
Price Impact
More from IMRX